SCHEMBL5047244

SCHEMBL5047244

O=C(O)C(Cc1ccccc1)NS(=O)(=O)c1ccc(-c2csc(-c3cccc4c3oc3ccccc34)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 12/20 0.53
MMP9 P14780 8/20 0.53
ADAMTS4 O75173 3/20 0.53
MMP13 P45452 2/20 0.51
MMP14 P50281 1/20 0.51
ADAMTS5 Q9UNA0 1/20 0.48
MMP1 P03956 1/20 0.48
MMP3 P08254 1/20 0.48
MMP7 P09237 1/20 0.48
PTPRF P10586 2/20 0.46
PTPN2 P17706 2/20 0.46
PTPN1 P18031 2/20 0.46
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4269569 0.86 MMP2 (0.66) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL5037617 0.85 MMP2 (0.53) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL5037620 0.85 MMP2 (0.53) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL5037885 0.82 MMP2 (0.52) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL5037883 0.82 MMP2 (0.52) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL4267878 0.81 PTPRF (0.44) ADAMTS5PTPRFPTPN2PTPN1MAPT
SCHEMBL27542487 0.73 MMP13 (0.65) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL4425847 0.73 MMP13 (0.65) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL5042554 0.73 MMP2 (0.49) MMP2MMP9ADAMTS4MMP13MMP14
SCHEMBL6545297 0.72 MMP2 (1.00) MMP2MMP9ADAMTS4MMP13MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC 2004-12-09 US claimed
EP-1633354-B1 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES INST FOR PHARM DISCOVERY INC (US) 2008-01-23 EP disclosed
EP-1633354-A2 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES The Institutes for Pharmaceutical Discovery, LLC (US) 2006-03-15 EP disclosed
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC 2004-12-09 US disclosed
WO-2004092146-A2 N- (((((1,3-THIAZOL-2-YL) AMINO) CARBONYL) PHENYL) SULFONYL) PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes PTP4A1, PTPRJ, PPM1B MMP2 3270/4885MMP9 4031/4885ADAMTS4 4122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.